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Summary The risk of idiopathic pneumonia syndrome (IPS) in patients with Hodgkin's disease (HD) undergoing high-dose chemotherapy
(HDC) is significant, and once developed IPS is potentially fatal. The aim of this study was to quantify this risk accurately and determine
prognostic factors for its development and course. Using a computerized database, all patients with HD treated with BCNU (carmustine)
containing HDC and haematopoietic support at The Royal Marsden between November 1985 and March 1994 were identified. Patient
characteristics, previous treatments, disease status at HDC, dose of BCNU, incidence and severity of IPS and survival were all determined
and analysed. During the study period, 94 patients received HDC, of whom 26 (28%) had a first episode of IPS within a year of HDC and 23
within 6 months. The median time to presentation after HDC was 93 days (range 12-336 days). The only factors that significantly increased
the risk of developing IPS on multivariate analysis were dose of BCNU (Pfor trend = 0.03) and female sex (P = 0.04). Of these 26 patients,
14 had complete resolution of all symptoms, three had persisting pulmonary symptoms at 6 months and the remaining nine died of IPS at a
median of 74 days (19-418 days). All the patients who died from IPS had the first symptoms within 6 months of HDC and all received doses
of BCNU > 475 mg m-2 (Pfor trend = 0.001). For women receiving > 475 mg m-2 the risk of death was significantly higher than for men (P =
0.035) but not for those receiving < 475 mg m-2. Previous lung disease, persisting residual disease before HDC, previous bleomycin or
previous mantle radiotherapy did not increase either the incidence of IPS or risk of a fatal outcome. We conclude that the main avoidable risk
factor for fatal IPS after HDC is dose of BCNU, and this is especially true for women. If < 475 mg m-2 is given, even patients with previous
mantle radiotherapy and/or previous bleomycin have a very low risk of developing fatal lung toxicity if lung function tests are normal.
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High-dose chemotherapy (HDC) with haematopoietic stem cell
support is now employed in several clinical situations in the
management of patients with Hodgkin's disease (HD) (Goldstone
et al, 1993). Rates of morbidity and mortality have improved with
better supportive measures and administration ofHDC at an earlier
phase in the course of the disease, but procedure-related mortality
remains in the region of 10-20% in most published series using
autologous bone marrow transplantation (ABMT) Jones et al,
1990; Reece et al, 1991; Bierman et al, 1993). Approximately 50%
ofthese fatalities will be as a consequence ofidiopathic pneumonia
syndrome (IPS). This presents with dyspnoea, pulmonary infil-
trates and fever, and the differential diagnosis is between infection
(often with an uncommon or unusual organism), pulmonary
involvement with HD, intrapulmonary haemorrhage or drug-
induced pneumonitis (Clark et al, 1993). The latter is most
frequently associated with high-dose BCNU (carmustine), which
induces interstitial fibrosis in a dose-dependent manner. (Litam
et al, 1981; Pecego et al, 1986; Weaver et al, 1993). The mecha-
nism is poorly understood but thought to involve toxic
metabolites that react with sulphydryl compounds (including
glutathione) resulting in neutralization. Depletion of such
compounds and inhibition of glutathione reductase in alveolar
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macrophages is postulated to increase the risk of oxidant injury
(Arrick et al, 1984; Clark et al, 1993).
Pulmonary toxicity may occur 9 days to 12 years after starting
BCNU (Durant etal, 1979) and may present with the sudden onset
of dyspnoea and progress rapidly to death, or be more insidious
with afatal outcome within 2 years (Phillips etal, 1983). In adose-
finding study published in 1990 using cyclophosphamide, etopo-
side and BCNU (Wheeler et al, 1990) 450 mg m-2 of BCNU was
the maximum tolerated dose, with a 5% mortality rate compared
with 22% observed following a dose of600 mg ni-2. Anotherstudy
using the same regimen and 600 mg m-2 BCNU, published the
following year, reported a 16% incidence of IPS and a 12%
mortality rate (Reece et al, 1991). A more recent series (Weaver
et al, 1993) reported no IPS in patients who received BCNU
300 mg m-2 a rate of23% in patients whoreceived 600 mg m-2.
The aim of our study was to quantify the risk and time of onset
of IPS at our own institution and determine the risk factors for its
development and prognostic factors for outcome.
PATIENTS AND METHODS
Using a computerized database, all patients with relapsed HD
treated with BCNU containing HDC and haematopoietic support
[either ABMT or peripheral stem cell transplantation (PSCT)]
between November 1985 and March 1994 were identified. Patient
characteristics, previous treatments, disease status at HDC, dose of
BCNU, incidence and severity of IPS and survival were all deter-
mined, with reference to the case notes when necessary. Episodes
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of pulmonary toxicity occurring after the first 12 months were
excluded.
The indications for HDC and assessment criteria are as
described previously (O'Brien et al, 1996). Toxicity was graded
according to the common toxicity criteria (National Cancer
Institute, 1988). All patients had pulmonary function tests before
HDC when possible. The conditioning regimen was a combination
ofmelphalan 80-140 mg m-2, BCNU 300-600 mg m-2 and etopo-
side 1200 mg m-2 (MBE), although etoposide was omitted if the
patients had recently failed etoposide-containing standard-dose
chemotherapy. The dose of BCNU used at the Royal Marsden
(RMH) was calculated on an individual basis but, in view of the
emerging evidence ofIPS athigherdoses, unitpolicy was changed
in 1990 so that all subsequent patients received less than 500 mg
m-2. The drugs were given as per standard protocols with cryopre-
served bone marrow or peripheral stem cell return on day 0.
Patients were nursed in either single rooms or four-bed side wards
without laminar flow. No bowel decontamination was carried out.
All patients received supportive antiseptic and antifungal mouth-
care, antibiotics if neutropenic and irradiated blood and platelet
support when required.
Possible prognostic factors for the development of and death
from IPS were investigated using the Kaplan-Meier method
Table 1 Patient characteristics
Atdiagnosis
Total
Men
Women
Stage
11
III
IV
Previous lung disease
Yes
No
Symptoms
A
B
94
60
34
5
21
33
35
6a
88
40
88
AtHDC
Age (years)
Median
Range
Performance status
0
1
2
Not known
Symptoms
A
B
Mediastinal/lung disease
Yes
No
First CR
Second or subsequent CR
Responding relapse
Resistant relapse
Primary refractory/untested
29
15-51
51
39
3
1
80
14
38
56
9
21
43
8
13
and the log-rank test. Multivariate analysis of risk factors
for the development of IPS was performed using the Cox propor-
tional hazards regression model with a stepwise selection proce-
dure. The number of deaths was too small to perform a
multivariate analysis.
RESULTS
Patient characteristics
During the study period, 94 patients with relapsed HD who had
undergone HDC were identified. There were 60 men and 34
women and the median age at HDC was 29 years (range 15-51
years). When diagnosed, five patients were stage I, 21 stage II, 33
stage III and 35 stage IV with 54 patients experiencing B symp-
toms. At HDC, 14 had B symptoms, 38 had lung or mediastinal
involvement and six had a history of non-malignant pulmonary
disease. Median performance status at HDC was 1. The disease
status of the patients at HDC was as follows: nine were in first
complete remission (CR), 21 in second or subsequent CR, 43 had
responding relapses, eight had resistant relapses and 13 primary
refractory disease or an untested relapse (Table 1). Follow-up
information was available up to November 1994 (median follow-
up 37 months, range 1-96 months). All patients had received
previous chemotherapy regimens (median 2), with 38 having
received previous bleomycin but none previous BCNU. Thirty-
three patients had received mantle radiotherapy to the medi-
astinum with a median dose of 35 Gy, range (25-50 Gy).
The conditioning regimen was MBE in 85 patients and
melphalan and BCNU in nine. The dose of BCNU was less than
475 mg m-2 in 41 patients, 475-525 mg m-2 in 34 and more than
525 mg m-2 in 19. Haematopoietic support took the form of autol-
ogous bone marrow in 89 patients (95%) and peripheral stem cells
in five (5%). Pulmonary function tests before HDC were
performed in 64 patients and the DLCO grade was 0/1 in 49 cases
and 2 or greater in the remaining 15.
Idiopathic pneumonia syndrome
At least one episode of IPS within the first year of HDC was
observed in 26 patients (28%) with a median time of presentation
of 91 days (range 12-336 days). Twenty-three out of twenty-six
patients developed symptoms within the first 6 months. All
patients presented with dyspnoea and/orcough and had pulmonary
infiltrates or fibrosis on chest radiography. Pulmonary function
tests and arterial blood gas estimations following HDC were
abnormal in all cases tested. Bronchoscopy and bronchoalveolar
lavage was performed in six patients. A total of 19 patients were
treated with steroids, five of whom died compared with one
fatality in the seven who did not receive steroids. Overall, 14
patients had complete resolution of symptoms and three had
persisting symptoms at 6 months. The remaining nine patients died
as a consequence of IPS at a median time from HDC of 74 days
(range 19-418 days).
Of the nine patients who died, four had lung function tests
performed before HDC and in three cases theresult was normal.Four
patients had lung or mediastinal disease at the time ofHDC and one
had previous lung disease. Two patients had previous mantle radio-
therapy, five had previous bleomycin and one had both before HDC.
All haddyspnoea (one patientgrade II,five grade HI,three grade IV)
and seven had a cough (six grade II, one grade III). All had
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aPrevious lung diseases were recurrent chest infections (2), recurrent
pneumothorax (1), pulmonary fibrosis (1), asthma (1) and idiopathic
interstitial pneumonitits (1).
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Table 2 Risk factors for IPS and death
Factor No. of No. of patients Univariate No. of Univariate
patients with IPS (%) P-value (IPS) fatalities (%) Pvalue
Previous bleomycin
Yes 38 13 (34) 5 (13)
No 56 13 (23) NS 4 (6) NS
Previous mantle
Yes 33 9 (27) 1 (3)
No 61 17 (28) NS 8 (13) NS
BCNU dose (mg m-2)
<475 41 6(15) 0(0)
475-525 34 11 (32) 4 (12)
> 525 19 9 (47) 0.006a 5 (26) 0.001a
Age (years)
<25 27 9 (33) 5 (19)
> 25 67 17 (25) NS 4 (6) NS
Previous lung disease
Yes 6 4(67) 1 (17)
No 88 22 (25) 0.08 8 (9) NS
Gender
Male 60 10 (17) 2 (3)
Female 34 16 (47) 0.001 7 (21) 0.01
DLCO grade
0-1 49 13 (27) 3 (6)
21 15 6 (40) NS 1 (7) NS
Lung/mediastinal involvement
Yes 38 13 (34) 4 (11)
No 56 13 (23) NS 5 (9) NS
aFor trend. NS, P> 0.1.
Table 3 Incidence of IPS by BCNU dose and gender
No. of No. of patients P.value No. of P.value
patients with IPS (%) fatalities (%)
< 475 mg m-2 BCNU
Men 31 4 (13) 0 (0)
Women 10 2 (20) NS 0 (0) NS
All 41 6 (15) 0 (0)
475-525 mg m-2 BCNU
Men 18 4 (22) 0 (0)
Women 16 7 (44) NS 4 (25) 0.035
All 34 11 (32) 4 (12)
> 525 mg m-2 BCNU
Men 11 2 (18) 2 (18)
Women 8 7 (87) 0.007 3 (37) NS
All 19 9 (47) 5 (26)
Men by BCNU dose NS 0.013
Women by BCNU dose 0.005 0.054
Total by BCNU dose 0.006 0.001
Total by gender 0.001 0.004
pulmonary infiltration on chest radiography and all had their first
episode ofIPS within 6 months ofHDC.Two patients hadpulmonary
function tests after high dose chemotherapy and both revealed grade
IV toxicity. Arterial blood gas estimation was abnormal in all cases
(toxicity: threegrade H,two grade III and fourgrade IV). All patients
weretreated with antibiotics and mechanical ventilation andeightout
ofninepatients received steroids. Thepathological diagnosis ofinter-
stitial pneumonitis was confirmed with open lung biopsy in one
patient and at post-mortem in six. At the time of death, six patients
were in remission and three had active Hodgkin's disease.
Prognostic factors
Univariate analysis of risk factors for developing IPS and prog-
nostic factors for fatal outcome are shown in Table 2. In terms of
risk factors for developing pulmonary toxicity, the only two that
reached conventional levels of statistical significance were female
sex and dose of BCNU (P = 0.001 and 0.006 respectively). These
were independently significant in the multivariate analysis
(gender, P = 0.04; BCNU, as a continuous variable, P = 0.03).
However, the increased risk with rising dose of BCNU appears to
be confined to women (Table 3 and Figure 1). The hazard ratios for
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Figure 1 Kaplan-Meier plot of probability of IPS within first year by dose of BCNU and gender
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incidence of IPS in the Cox analysis were 3.2 for female sex and
1.005 per mg increase for dose ofBCNU.
The same two factors were also the only ones that significantly
predicted for death from IPS (female sex, P = 0.001; dose of
BCNU, P = 0.001) in the univariate analysis, with all deaths
occurring in patients who received more than 475 mg m-2 BCNU
(Table 2 and 3) and men also exhibiting an increased risk at
higher doses.
DISCUSSION
This study examined the incidence and risk factors for IPS in 94
patients with relapsed HD treated with HDC and ABMT/PSCT at
the RMH between October 1985 and March 1994. High-dose
consolidation of second and subsequent remissions is increasingly
employed in the management of HD but the risk factors for the
development ofIPS have not been fully elucidated. The aim ofthis
study was to quantify the risk and identify the prognostic factors
for outcome.
Previous studies have demonstrated an overall mortality associ-
ated with HDC for HD using ABMT of between 10% and 20%
(Reece et al, 1991; Jones et al, 1990; Bierman et al, 1993; O'Brien
et al, 1996). The rates with individual regimens will depend on the
doses and toxicities of the drugs in the conditioning therapy, as
well as the amount of previous chemotherapy and irradiation and
the number of patients in therapy-resistant relapse (Ahmed et al,
1990). The type of haematopoietic support will also influence the
risk as the period of neutropenia is less prolonged with PSCT and
hence the frequency ofinfectious pulmonary complications would
be reduced.
Drug-induced pneumonitis has been a well-recognised compli-
cation oftreatment with BCNU since the 1970s (Collis et al, 1991)
and the risk rises steadily with increasing dose (Aronin et al,
1980). Other risk factors are pre-existing lung disease and
smoking (Kreisman et al, 1992), although the formerjust failed to
reach statistical significance in the current study. In the light ofthe
evidence that the incidence of IPS was reduced at lower doses of
BCNU, the treatment policy at the RMH was changed in 1990 so
that all doses ofBCNU were < 500 mg m-2. Since that time, some
pulmonary toxicity has been observed but there have been no fatal
episodes of drug-induced pneumonitis, and our study confirms
that increasing doses of BCNU are associated with a significantly
higher risk for developing fatal lung toxicity (P = 0.001), with no
deaths occurring in patients receiving < 475 mg m-2.
Female gender was arisk factorforboth the development ofIPS
(P = 0.001) and for a fatal outcome (P = 0.01). The phenomenon
of increased cardiopulmonary toxicity in women treated for HD
has been noted previously, but the mechanism is obscure (Lund et
al, 1996). One assumes that drug handling and pharmacokinetics
between the sexes may differ, but there is scant evidence for this
supposition.
Patients who had received previous bleomycin or mantle radio-
therapy did not have a higher risk of developing IPS in our study;
this probably reflects the policy ofadjusting the dose ofBCNU in
cases ofabnormal lung function and omitting the drug altogether if
the abnormality was severe. No adverse risk was associated with
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increasing age (cut-off > 25 years), although the low numbers of
patients of age > 50 years does not preclude this possibility, as
suggested by prior studies (Miller et al, 1996).
The predominant symptoms and signs associated with clinical
BCNU-induced pulmonary toxicity were dyspnoea and dry
hacking cough. Physical examination was non-specific and some
patients had basal crepitations apparent on auscultation. When the
patients presented with pulmonary symptoms the chest radiograph
was abnormal in all cases. The main radiographic finding was
bibasal interstitial infiltrates with a reticular-nodular pattern
(75%); other signs detected were pulmonary fibrosis (25%),
pleural effusion (19%) and pulmonary oedema (11%). These radi-
ographic changes are similar to those in a previous report of chest
radiograph abnormalities in patients with lymphoma following
HDC and ABMT (Millard et al, 1991). Pulmonary function studies
generally showed varying restrictive defects and abnormality in
the DLCO. This abnormality may precede radiographic changes
and progress after discontinuing therapy. As BCNU can cause
potentially lethal pulmonary toxicity if given inappropriately,
pulmonary function tests should always be performed before the
administration of this drug and used to calculate the correct dose.
Once BCNU-related pulmonary toxicity occurs, the outcome is
variable. The disease often progresses despite institution of inten-
sive treatment with antibiotics, steroids and mechanical ventila-
tion. In our study, the use of steroids was not controlled, but in
general was given to those with the most severe symptoms and
signs. This may well explain the higher fatality rate in those
receiving steroids (five out ofnineteen patients, 26%) compared to
those who did not (one out of seven patients, 14%), although with
such small numbers definitive conclusions are not possible.
The incidence of pulmonary toxicity in our study was 28% (26
out of94 patients), and the mortality related to IPS was 35% (9 out
of26). Histological confirmation was obtained in seven ofthe nine
patients who died (one at open lung biopsy and six at post-
mortem), with pathological features typical ofcytotoxic injury.
We conclude that the main risk factors for IPS in HDC are dose
ofBCNU and female sex. Patients ofeither gender given less than
475 mg m-2 BCNU have a very low risk of developing fatal lung
toxicity, and previous mantle radiotherapy and/or previous
bleomycin do not appear to greatly increase this risk if lung func-
tion tests before HDC are within normal limits. A history of non-
malignant pulmonary disease probably increases the risk of IPS
but not ofa fatal outcome.
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